Table 3.
Treatment failure (all events)
| Year | ||||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| Any reason | ||||||
| Number at risk | ||||||
| Carbamazepine | 225 | 160 | 106 | 65 | 26 | 7 |
| Gabapentin | 195 | 133 | 87 | 51 | 24 | 8 |
| Lamotrigine | 266 | 178 | 121 | 84 | 42 | 11 |
| Topiramate | 207 | 136 | 81 | 54 | 24 | 7 |
| Oxcarbazepine | 118 | 73 | 29 | 3 | ||
| Percentage still on drug (95% CI) | ||||||
| Carbamazepine | 65 (61 to 70) | 57 (52 to 62) | 53 (47 to 58) | 50 (44 to 56) | 45 (38 to 52) | 40 (31 to 49) |
| Difference in percentage without failure compared with carbamazepine (95% CI) | ||||||
| Gabapentin | −8 (−15 to −1) | −8 (−16 to −1) | −10 (−18 to −2) | −11 (−19 to −3) | −7 (−16 to 2) | −4 (−15 to 7) |
| Lamotrigine | 12 (6 to 19) | 8 (1 to 15) | 6 (−2 to 13) | 4 (−4 to 12) | 6 (−4 to 15) | 11 (1 to 20) |
| Topiramate | −5 (−12 to 2) | −9 (−16 to −2) | −8 (−16 to −1) | −8 (−16 to 0) | −5 (−14 to 4) | −4 (−16 to 7) |
| Oxcarbazepine | −2 (−11 to 8) | −1 (−11 to 9) | −1 (−13 to 10) | −1 (−14 to 12) | ||
| For unacceptable adverse events | ||||||
| Percentage without failure (95% CI) | ||||||
| Carbamazepine | 74% (70 to 79) | 70% (65 to 75) | 69% (64 to 74) | 69% (64 to 74) | 68% (63 to 73) | 68% (63 to 73) |
| Difference in percentage without failure compared with carbamazepine (95% CI) | ||||||
| Gabapentin | 9 (3 to 15) | 11 (4 to 17) | 11 (4 to 17) | 11 (4 to 17) | 12 (5 to 18) | 12 (5 to 18) |
| Lamotrigine | 10 (4 to 16) | 11 (4 to 17) | 10 (4 to 17) | 11 (4 to 17) | 10 (3 to 17) | 10 (3 to 17) |
| Topiramate | 0 (−6 to 6) | 0 (−7 to 7) | −1 (−8 to 6) | 0 (−7 to 7) | 1 (−7 to 8) | −2 (−10, 7) |
| Oxcarbazepine* | 3 (−6 to 11) | 4 (−5 to 13) | 4 (−6 to 13) | 5 (−5 to 15) | ||
| For inadequate seizure control | ||||||
| Percentage without failure (95% CI) | ||||||
| Carbamazepine | 92 (55 to 95) | 87 (41 to 91) | 84 (33 to 88) | 82 (28 to 86) | 77 (20 to 83) | 73 (15 to 81) |
| Difference in percentage without failure compared with carbamazepine (95% CI) | ||||||
| Gabapentin | −17 (−22 to −11) | −19(−25 to −13) | −21 (−27 to −14) | −21 (−29 to −14) | −18 (−27 to −10) | −15 (−26 to −4) |
| Lamotrigine | 0 (−4 to 4) | −2 (−8 to 3) | −4 (−10 to 2) | −6 (−12 to 1) | −3 (−12 to 5) | 1 (−9 to 12) |
| Topiramate | −4 (−9 to 0) | −8 (−14 to −3) | −7 (−13 to 0) | −7 (−14 to 0) | −5 (−13 to 4) | −2 (−13 to 9) |
| Oxcarbazepine* | −4 (−9 to 2) | −4 (−11 to 4) | −4 (−14 to 5) | −6 (−17 to 5) | ||
*
Figures in this row use data for oxcarbazepine and carbamazepine only from patients randomised after June 1, 2001.